On Saturday afternoon, the ASCO town hall convened to share different perspectives on administrative burden, pharmacy benefit managers, and clinical pathways.
Nathan R Handley, MD, explains the extent to which unplanned acute hospital care is a concern for the health care system and ways in which care coordination and clinical pathways can help decrease unnecessary spending.
A Novel Clinical Pathways Approach to Delivering Regional-Based Clinical Trials and Patient Care in a Hybrid Academic-Community-Based System
Since 2015, the Levine Cancer Institute, Atrium Health, has created and utilized the Electronically Accessible Pathways, which has helped drive standardization and enhance provider and patient diagnostic and treatment knowledge across its regional network.
Sowmya Josyula, MD, MPH, and Bobby Daly, MD, MBA, discuss the most commonly recognized administrative barriers faced by physicians using oncology clinical pathways and argue that addressing these burdens is crucial in ensuring provider adoption and seamless patient care.
Adam M Brufsky, MD, PhD, discusses some of the key topics and data for examining the clinical and cost implications of HER-positive breast cancer care in the value-based care era.
Dawn Holcombe, MBA, FACMPE, ACHE, explains why private payers are making the transition from traditional reimbursement models to value-based models at a slow pace and how OCM performance results may impact this transition.
A panel at the SGO 2018 Annual Meeting on Women’s Cancer convened to achieve consensus on PARP inhibitor use for the treatment and maintenance of ovarian cancer in the context of current standards.
Robin T Zon, MD, FACP, FASCO, and Bobby Daly, MD, MBA, discuss ASCO's recently published results of an evaluation of national pathway vendors against the Criteria for High-Quality Clinical Pathways.
Texas Oncology and Aetna partnered to provide a practice-based program that reduced costs while maintaining adherence to treatment pathways and patient satisfaction in Medicare patients.
Bobby Daly, MD, MBA, and Ray D Page, DO, PhD, discuss the ramifications of clinical pathway vendor conflicts of interest and the potential issues of full transparency on the part of committee members.